The von Hippel-Lindau tumor suppressor gene and kidney cancer

Clinical Cancer Research

Volumn 10, Issue 18 II, 2004, Pages

  Kaelin Jr , William G ^a   Yang, James ^b   Linehan, W Marston ^b   Iliopoulos, Othon ^b   Atkins, Michael ^b   George, Daniel ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DNA TOPOISOMERASE INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR; OXYGEN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN INHIBITOR; SORAFENIB; SUNITINIB; THIOREDOXIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; VON HIPPEL LINDAU PROTEIN;

CANCER INHIBITION; CARCINOGENESIS; CELL HYPOXIA; CHROMOSOME 3P; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; VASCULAR TUMOR; VON HIPPEL LINDAU TUMOR SUPPRESSOR GENE; XENOGRAFT;

CARCINOMA, RENAL CELL; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 4644363095     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-sup-040025     Document Type: Conference Paper

References (92)

1. Comings DE. A general theory of carcinogenesis. Proc Nat Acad Sci USA 1973;70:3324-8.
2. Knudson AG Jr, Strong LC, Anderson DE. Heredity and cancer in man. Prog Med Genet 1973;9:113-58.
3. Fearon ER, Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 1990;61:759-67.
4. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
5. Maher E, Kaelin WG. von Hippel-Lindau disease. Medicine 1997; 76:381-91.
6. Kim WY and Kaelin WG. The role of VHL gene mutation in human cancer. J Clin Oncol. In press 2004.
7. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease Tumor Suppressor Gene. Science 1993;260:1317-20.
8. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149:2089-94.
9. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-68.
10. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
11. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 1996;93:10589-94.
12. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
13. Woodward E, Buchberger A, Clifford S, Hurst L, Affara N, Maher E. Comparative sequence analysis of the VHL tumor suppressor gene. Genomics 2000;65:253-65.
14. Epstein A, Gleadle J, McNeill L, et al. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
15. Adryan B, Decker H-JH, Papas TS, Hsu T. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 2000;19:2803-11.
16. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996;75:231-8.
17. Nagashima Y, Miyagi Y, Udagawa K, et al. Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization. J Pathol 1996;180:271-4.
18. Richards F, Schofield P, Fleming S, Maher E. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Human Mol Genet 1996;5:639-44.
19. Kessler P, Vasavada S, Rackley R, et al. Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1995;1:457-66.
20. Schoenfeld A, Davidowitz E, Burk R. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1 1998;95:8817-22.
21. Blankenship C, Naglich J, Whaley J, Seizinger B, Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-35.
22. Iliopoulos O, Ohh M, Kaelin W. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-6.
23. Schoenfeld A, Davidowitz E, Burk R. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Int J Cancer 2001;91:457-67.
24. Corless CL, Kibel A, Iliopoulos O, Kaelin WGJ. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum Pathol 1997;28:459-64.
25. Duan DR, Humphrey JS, Chen DYT, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995;92:6495-9.
26. Ye Y, Vasavada S, Kuzmin I, Stackhouse T, Zbar B, Williams B. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 1998;78:62-9.
27. Lee S, Neumann M, Stearman R, et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999;19: 1486-97.
28. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002; 22:5319-36.
29. Shiao YH, Resau JH, Nagashima K, Anderson LM, Ramakrishna G. The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res 2000;60:2816-9.
30. Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003;13:55-60.
31. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349: 419-21.
32. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003;22:4082-90.
33. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002;99: 13459-64.
34. Bruick R, McKnight S. A Conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40.
35. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
36. Yu F, White S, Zhao Q, Lee F. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001;98:9630-5.
37. Jaakkola P, Mole D, Tian Y, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
38. Okuda H, Saitoh K, Hirai S, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001;276:43611-7.
39. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-1-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000;275:20700-6.
40. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001;61:1768-75.
41. Okuda H, Hirai S, Takaki Y, et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-7.
42. Mukhopadhyay D, Knebelmann B, Cohen H, Ananth S, Sukhatme V. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
43. Cohen H, Zhou M, Welsh A, et al. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 1999;266:43-50.
44. Pioli PA, Rigby WF. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J Biol Chem 2001;276:40346-52.
45. Kuznetsova AV, Meller J, Schnell PO, et al. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 2003;100:2706-11.
46. Na X, Duan HO, Messing EM, et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003;22:4249-59.
47. Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT. The von Hippel-Lindau (VHL) tumor suppressor stabilizes novel PHD protein Jade-1. J Biol Chem 2002;277:39887-98.
48. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun 2002; 294:700-9.
49. Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2002;277:4656-62.
50. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
51. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58:4957-62.
52. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.
53. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
54. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
55. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-55.
56. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004;2:89-95.
57. Kwiatkowski DJ. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther 2003;2:471-6.
58. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999;59: 1206-11.
59. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999;104:687-95.
60. Hino O, Kobayashi T, Momose S, Kikuchi Y, Adachi H, Okimoto K. Renal carcinogenesis: genotype, phenotype and dramatype. Cancer Sci 2003;94:142-7.
61. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-58.
62. Liu M, Poellinger L, Walker C. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 2003;63:2675-80.
63. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor lalpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
64. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003;278:29655-60.
65. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
66. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003;63:5173-7.
67. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med 2002;8:S55-61.
68. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
69. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-82.
70. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor I transcriptional activation pathway. Cancer Res 2002;62:4316-24.
71. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors I-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
72. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3: 233-44.
73. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 2003;3:363-75.
74. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
75. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003;4:757-63.
76. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60:4819-24.
77. Yang J, Haworth L, Sherry R, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
78. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
79. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103: 159-65.
80. Knebelmann B, Ananth S, Cohen H, Sukhatme V. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-31.
81. de Paulsen N, Brychzy A, Fournier M-C, et al. Role of transforming growth factor-alpha in VHL-/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 13:1387-92.
82. Sweeney W, Chen Y, Nakanishi K, Frost P, Avner E. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 2000;57:33-40.
83. Lowden D, Lindemann G, Merlino G, Barash B, Calvet J, Gattone V. n. Renal cysts in transgenic mice expressing transforming growth factor-alpha. J Lab Clin Med 1994;124:386-94.
84. Haase V, Glickman J, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001;98:1583-8.
85. Ma W, Tessarollo L, Hong SB, et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 2003;63: 5320-8.
86. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
87. Ivanov S, Kuzmin I, Wei M-H, et al. Down-regulation of transmembrance carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-601.
88. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate K. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
89. Wiesener M, Munchenhagen P, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas. Cancer Res 2001; 61:5215-22.
90. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
91. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-83.
92. Kaelin WG Jr. Gleevec: prototype or outlier? Sci STKE, 2004: PE12. 2004.